Oxygen transport and utilisation during exercise in cystic fibrosis: contributors to exercise intolerance

Zoe L Saynor, Mathieu Gruet, Paula Rodriguez-Miguelez, Ryan A Harris, Zoe L Saynor, Mathieu Gruet, Paula Rodriguez-Miguelez, Ryan A Harris

Abstract

New findings: What is the topic of this review? This review highlights the central and peripheral mechanisms that alter oxygen transport and utilisation and thereby contribute to exercise limitation in people with cystic fibrosis, considering also viable therapeutic targets for intervention. What advances does it highlight? Although traditionally considered a respiratory condition, pathological intramuscular and cardiovascular changes in people with cystic fibrosis appear to be key determinants of exercise intolerance up until the later stages of respiratory disease. Even young, habitually active patients with normal lung function experience multisystemic abnormalities, which play a role in exercise intolerance.

Abstract: Cystic fibrosis (CF) is a complex condition, commonly associated with exercise limitation. The mechanisms responsible for this in CF are of interest, given that lower aerobic fitness is associated with an increased risk of being hospitalised with pulmonary exacerbation, a poorer quality of life and a poorer prognosis. Pathophysiological changes in lung function are considered central to CF, and may contribute to exercise limitation. However, it is now clear that the pathogenesis of exercise limitation in this population is multifactorial, with alterations in cardiovascular, muscle and pulmonary function contributing. Whilst some of these changes are attributable to respiratory disease per se, the CF transmembrane conductance regulator protein is also found in skeletal muscle and the vascular endothelium and can directly alter central and localised oxygen delivery, as well as the ability to effectively extract and utilise oxygen at the myocyte level. Since intense exercise poses considerable challenges to arterial oxygen content and/or blood flow and its supply to the working skeletal muscle, evaluating the exercise physiology of people with CF has helped us understand the mechanisms underlying exercise intolerance. Through several investigations over recent years, we have collectively demonstrated that people with CF exhibit reduced skeletal muscle oxygen extraction and utilisation during exercise, with a lesser contribution from haemodynamic or chronotropic mechanisms. Taken together, our findings highlight the importance of targeting mechanisms of skeletal muscle oxygen utilisation in CF to improve exercise tolerance and we offer potential therapeutic interventional strategies.

Keywords: O2 delivery; O2 utilisation; cystic fibrosis; exercise intolerance; haemodynamics.

© 2020 The Authors. Experimental Physiology © 2020 The Physiological Society.

References

REFERENCES

    1. Causer, A. J., Shute, J. K., Cummings, M. H., Shepherd, A. I., Gruet, M., Costello, J. T., … Connett, G. (2020). Circulating biomarkers of antioxidant status and oxidative stress in people with cystic fibrosis: A systematic review and meta-analysis. Redox Biology, 32, 101436.
    1. Chen, H., Liu, L. L., Ye, L. L., McGuckin, C., Tamowski, S., Scowen, P., … Duan, D. (2004). Targeted inactivation of cystic fibrosis transmembrane conductance regulator chloride channel gene prevents ischemic preconditioning in isolated mouse heart. Circulation, 110, 700-704.
    1. Divangahi, M., Balghi, H., Danialou, G., Comtois, A. S., Demoule, A., Ernest, S., … Radzioch, D. (2009). Lack of CFTR in skeletal muscle predisposes to muscle wasting and diaphragm muscle pump failure in cystic fibrosis mice. PLoS Genetics, 5, e1000586.
    1. Eising, J. B., van der Ent, C. K., Teske, A. J., Vanderschuren, M. M., Uiterwaal, C. S., & Meijboom, F. J. (2018). Young patients with cystic fibrosis demonstrate subtle alterations of the cardiovascular system. Journal of Cystic Fibrosis, 17, 643-649.
    1. Erickson, M. L., Seigler, N., McKie, K. T., McCully, K. K., & Harris, R. A. (2015). Skeletal muscle oxidative capacity in patients with cystic fibrosis. Experimental Physiology, 100, 545-552.
    1. Giacchi, V., Rotolo, N., Amato, B., Di Dio, G., Betta, P., La Rosa, M., … Sciacca, P. (2015). Heart involvement in children and adults with cystic fibrosis: Correlation with pulmonary indexes and inflammation markers. Heart, Lung and Circulation, 24, 1002-1010.
    1. Gruet, M., Troosters, T., & Verges, S. (2017). Peripheral muscle abnormalities in cystic fibrosis: Etiology, clinical implications and response to therapeutic interventions. Journal of Cystic Fibrosis, 16, 538-552.
    1. Hart, P., Warth, J. D., Levesque, P. C., Collier, M. L., Geary, Y., Horowitz, B., & Hume, J. R. (1996). Cystic fibrosis gene encodes a cAMP-dependent chloride channel in heart. Proceedings of the National Academy of Sciences, USA, 93, 6343-6348.
    1. Khalaf, M. M., Scott-Ward, T. S., Causer, A. J., Saynor, Z. L., Shepherd, A. I., Gorecki, D., … Shute, J. K. (2020). Cystic fibrosis transmembrane conductance regulator (CFTR) in human lung microvascular endothelial cells controls oxidative stress, reactive oxygen-mediated cell signalling and inflammation. Frontiers in Physiology, 11, 879.
    1. Kusenbach, G., Wieching, R., Barker, M., Hoffmann, U., & Essfeld, D. (1999). Effects of hyperoxia on oxygen uptake kinetics in cystic fibrosis patients as determined by pseudo-random binary sequence exercise. European Journal of Applied Physiology and Occupational Physiology, 79, 192-196.
    1. Labombarda, F., Saloux, E., Brouard, J., Bergot, E., & Milliez, P. (2016). Heart involvement in cystic fibrosis: A specific cystic fibrosis-related myocardial changes? Respiratory Medicine and Research, 118, 31-38.
    1. Lamhonwah, A. M., Bear, C. E., Huan, L. J., Chiaw, P. K., Ackerley, C. A., & Tein, I. (2010). Cystic fibrosis transmembrane conductance regulator in human muscle: Dysfunction causes abnormal metabolic recovery in exercise. Annals of neurology, 67, 802-808.
    1. Linsdell, P., & Hanrahan, J. W. (1998). Glutathione permeability of CFTR. American Journal of Physiology. Cell Physiology, 275, C323-C326.
    1. Lubamba, B., Lebacq, J., Reychler, G., Marbaix, E., Wallemacq, P., Lebecque, P., & Leal, T. (2011). Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice. European Respiratory Journal, 37, 72-78.
    1. Nixon, P. A., Orenstein, D. M., Curtis, S. E., & Ross, E. A. (1990). Oxygen supplementation during exercise in cystic fibrosis1-3. The American Review of Respiratory Disease, 142, 807-811.
    1. Poore, S., Berry, B., Eidson, D., McKie, K. T., & Harris, R. A. (2013). Evidence of vascular endothelial dysfunction in young patients with cystic fibrosis. Chest, 143, 939-945.
    1. Reuveny, R., DiMenna, F. J., Gunaratnam, C., Arad, A. D., McElvaney, G. N., Susta, D., … Moyna, N. M. (2020). High-intensity interval training accelerates oxygen uptake kinetics and improves exercise tolerance for individuals with cystic fibrosis. BMC Sports Science, Medicine and Rehabilitation, 12, 9.
    1. Rodriguez-Miguelez, P., Ishii, H., Seigler, N., Crandall, R., Thomas, J., Forseen, C., … Harris, R. A. (2019). Sildenafil improves exercise capacity in patients with cystic fibrosis: A proof-of-concept clinical trial. Therapeutic Advances in Chronic Disease, 10, 204062231988787.
    1. Rodriguez-Miguelez, P., Lee, N., Tucker, M. A., Csányi, G., McKie, K. T., Forseen, C., & Harris, R. A. (2018). Sildenafil improves vascular endothelial function in patients with cystic fibrosis. American Journal of Physiology. Heart and Circulatory Physiology, 315, H1486-H1494.
    1. Rodriguez-Miguelez, P., Seigler, N., Ishii, H., Crandall, R., McKie, K. T., Forseen, C., & Harris, R. A. (2020). Exercise intolerance in cystic fibrosis: Importance of skeletal muscle. Medicine & Science in Sports & Exercise, doi:10.1249/MSS.0000000000002521.
    1. Rodriguez-Miguelez, P., Thomas, J., Seigler, N., Crandall, R., McKie, K. T., Forseen, C., & Harris, R. A. (2016). Evidence of microvascular dysfunction in patients with cystic fibrosis. American Journal of Physiology. Heart and Circulatory Physiology, 310, H1479-H1485.
    1. Saynor, Z. L., Barker, A. R., Oades, P. J., & Williams, C. A. (2014a). The effect of ivacaftor in adolescents with cystic fibrosis (G551D mutation): An exercise physiology perspective. Pediatric Physical Therapy, 26, 454-461.
    1. Saynor, Z. L., Barker, A. R., Oades, P. J., & Williams, C. A. (2014b). Impaired aerobic function in patients with cystic fibrosis during ramp exercise. Medicine and Science in Sports & Exercise, 46, 2271-2278.
    1. Saynor, Z. L., Barker, A. R., Oades, P. J., & Williams, C. A. (2016). Impaired pulmonary VO2 kinetics in cystic fibrosis depend on exercise intensity. Medicine & Science in Sports & Exercise, 48, 2090-2099
    1. Sellers, Z. M., Kovacs, A., Weinheimer, C. J., & Best, P. M. (2013). Left ventricular and aortic dysfunction in cystic fibrosis mice. Journal of Cystic Fibrosis, 12, 517-524.
    1. Sperandio, P. A., Oliveira, M. F., Rodrigues, M. K., Berton, D. C., Treptow, E., Nery, L. E., … Neder, J. A. (2012). Sildenafil improves microvascular O2 delivery-to-utilization matching and accelerates exercise O2 uptake kinetics in chronic heart failure. American Journal of Physiology. Heart and Circulatory Physiology, 303, H1474-H1480.
    1. Taylor-Cousar, J., Wiley, C., Felton, L., Clair, C. S., Jones, M., Curran-Everett, D., … Saavedra, M. (2015). Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease. Journal of Cystic Fibrosis, 14, 228-236.
    1. Tousson, A., Van Tine, B. A., Naren, A. P., Shaw, G. M., & Schwiebert, L. M. (1998). Characterization of CFTR expression and chloride channel activity in human endothelia. American Journal of Physiology. Cell Physiology, 275, C1555-C1564.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe